Bokf Na Invests $3.54 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Bokf Na acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 8,589 shares of the company’s stock, valued at approximately $3,537,000.

Several other hedge funds have also added to or reduced their stakes in the business. Signaturefd LLC increased its position in Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after acquiring an additional 26 shares during the period. Commonwealth Equity Services LLC increased its holdings in Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Medpace by 5.3% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after purchasing an additional 39 shares during the last quarter. Journey Advisory Group LLC lifted its holdings in Medpace by 1.9% during the 2nd quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after buying an additional 44 shares during the period. Finally, Coldstream Capital Management Inc. grew its position in shares of Medpace by 5.0% in the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after buying an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. TD Cowen cut their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Truist Financial assumed coverage on shares of Medpace in a research note on Thursday, August 1st. They issued a “hold” rating and a $415.00 price objective on the stock. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Moderate Buy” and a consensus price target of $423.00.

Medpace Stock Up 2.0 %

Shares of NASDAQ MEDP opened at $351.67 on Friday. Medpace Holdings, Inc. has a 12-month low of $227.21 and a 12-month high of $459.77. The firm has a market cap of $10.90 billion, a PE ratio of 35.85, a P/E/G ratio of 1.74 and a beta of 1.35. The company’s fifty day simple moving average is $384.27 and its 200 day simple moving average is $393.43.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period last year, the business posted $1.93 EPS. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, equities analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.